Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma

Bibliographic Details
Main Authors:	Kate E. Beekman, BS, Lily M. Parker, BS, Danielle K. DePalo, MD, Kelly M. Elleson, MD, Amod A. Sarnaik, MD, Kenneth Y. Tsai, MD, PhD, Bethany M. Withycombe, PharmD, BCOP, Jonathan S. Zager, MD
Format:	Article
Language:	English
Published:	Elsevier 2023-03-01
Series:	JAAD Case Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512623000176

Similar Items

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
by: Erin M. McClure, BS, et al.
Published: (2023-02-01)

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
by: Jonathan T. Blackmon, et al.
Published: (2017-07-01)

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec
by: Jamie Lebhar, BME, et al.
Published: (2023-10-01)

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection
by: Leonid Shmuylovich, MD, PhD, et al.
Published: (2022-11-01)

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
by: Neha Singh, BS, et al.
Published: (2023-06-01)

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy
by: Jason M. Rizzo, MD, PhD, et al.
Published: (2018-05-01)

Talimogene laherparepvec: First in class oncolytic virotherapy
by: Robert M. Conry, et al.
Published: (2018-04-01)

Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec
by: Matthew M. Wallace, MD, et al.
Published: (2024-01-01)

Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases
by: Jonathan T. Blackmon, et al.
Published: (2017-05-01)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanomaResearch in context
by: Robert H.I. Andtbacka, et al.
Published: (2019-09-01)

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)
by: Matthew C Perez, et al.
Published: (2019-06-01)

Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC)
by: Jennifer Gardner, et al.
Published: (2018-07-01)

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
by: Howard L. Kaufman, et al.
Published: (2022-02-01)

Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec
by: Yonglu Che, MD, PhD, et al.
Published: (2024-04-01)

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
by: Lillian Sun, et al.
Published: (2018-05-01)

Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
by: Jennifer Gardner, et al.
Published: (2022-10-01)

Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient
by: Kelsey E. Hirotsu, MD, et al.
Published: (2021-07-01)

Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)
by: James Sun, et al.
Published: (2020-07-01)

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
by: Umang Swami, et al.
Published: (2019-01-01)

Radar-Guided Localization and Resection for Metastatic Nodal and Soft Tissue Melanoma: A Single-Institution Retrospective Study
by: Kate E. Beekman, et al.
Published: (2024-02-01)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
by: Ann W. Silk, et al.
Published: (2016-09-01)

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
by: Megumi Kai, et al.
Published: (2021-11-01)

Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient
by: Max Miller, et al.
Published: (2023-06-01)

409 A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO)
by: John Stewart, et al.
Published: (2020-11-01)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
by: Erika Richtig, et al.
Published: (2021-02-01)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
by: Jens Tijtgat, et al.
Published: (2021-10-01)

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Published: (2021-10-01)

Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response
by: Pablo Iglesias, et al.
Published: (2018-11-01)

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
by: Robert H. I. Andtbacka, et al.
Published: (2019-06-01)

Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
by: Dean A Fergusson, et al.
Published: (2019-12-01)

Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
by: Anne Fröhlich, et al.
Published: (2020-05-01)

Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
by: Kleemann J, et al.
Published: (2021-07-01)

Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus <i>Talimogene Laherparepvec</i> with Small Molecule Inhibitors
by: Stavros Sotiriadis, et al.
Published: (2024-05-01)

Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report
by: Saurabh D. Chitnis, et al.
Published: (2024-05-01)

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
by: David M. Miller, et al.
Published: (2018-11-01)

Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
by: Yifan Hong, et al.
Published: (2024-12-01)

A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma
by: Goar Egoryan, et al.
Published: (2024-12-01)

A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors
by: Lucas Moreno, et al.
Published: (2023-05-01)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
by: Sant P. Chawla, et al.
Published: (2023-05-01)

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma
by: Malidi Ahamadi, et al.
Published: (2023-02-01)